Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MDRNA, a biotechnology company, has entered into an agreement with Roche, pursuant to which Roche will obtain a non-exclusive license to a portion of MDRNA's technology platform for the development of RNAi-based therapeutics. Terms of the agreement were not disclosed.
Subscribe to our email newsletter
Michael French, president and CEO of MDRNA, said: “We are pleased to have Roche recognize the value of our drug discovery platform. To have a portion of our platform in-licensed by Roche, a company with a significant effort in RNAi-based therapeutics, is a great testament to our intellectual property estate as well as the strong science being performed by our researchers.
“This agreement provides us the necessary resources to continue to pursue multiple, non-exclusive research collaborations, as well as future financing opportunities. We look forward to working with Roche to capitalize on the platform capability we are licensing to them as part of this agreement.”